http://www.biocurex.com/curexhtml/ne...

As a result, scientists from seven centers located in the USA, Europe, Japan or Israel have proposed, agreed, or have expressed an interest in carrying out collaborations with BioCurex.

The Company has previously engaged in collaborative work with three of these laboratories and the results have been published or presented at other congresses. The conversations with scientists from these groups centered on future work using the RECAF-ELISA format.

Three other collaborations relate to the validation and systematic study of RECAF on serum samples and a fourth one is focused on tumor imaging using anti-RECAF antibodies. The feasibility of these collaborations is not the same for all of them and two might require securing funds to carry out the work before starting.

USA Abbott (IMAGING), Inverness (ELISA), Goshen (ELISA)

Europe University of Munich, Germany (?)

Japan (VALIDATION) Dr. Kazuhita Taketa, M.D., head of the Clinical Trial Center and emeritus professor, Okayama University. Dr. Taketa has worked for more than 30 years on liver diseases and cancer markers and he has published numerous papers on the topic. The project will involve major research and hospital centers in Japan, including the prestigious Shigei Medical Research Institute and the Sapporo Social Insurance General Hospital.

Israel ? (ELISA)

also....I do wonder who invited Dr. Moro ? Abbott? "Finally, following the presentations, Dr. Moro was invited to present results on RECAF at another international symposium on cancer markers to be held in Barcelona, in February next year."